Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 8/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | PTPRB | P23467 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6421010 | 0.96 | GRIN2B (0.53) | GRIN2BCYP2D6CYP2C9KDM4EPKM | |
| SCHEMBL5399454 | 0.86 | GRIN2B (0.47) | GRIN2BCYP2D6CYP2C9KDM4EPKM | |
| SCHEMBL5392911 | 0.84 | GRIN2B (0.48) | GRIN2BCYP2D6CYP2C9KDM4EPKM | |
| SCHEMBL6353754 | 0.83 | ALDH1A1 (0.44) | GRIN2BCYP2D6CYP2C9KDM4EPKM | |
| SCHEMBL6215082 | 0.76 | PTPRB (0.43) | CYP2D6KDM4EPKMPTPRBPTPN11 | |
| SCHEMBL6343306 | 0.76 | SIGLEC9 (0.51) | GRIN2BCYP2D6CYP2C9KDM4ECYP3A4 | |
| SCHEMBL6148442 | 0.75 | CYP2D6 (0.64) | GRIN2BCYP2D6CYP2C9KDM4EPKM | |
| SCHEMBL6346955 | 0.74 | NOS2 (0.54) | GRIN2BPTPRBPTPN11MEN1KMT2A | |
| SCHEMBL6421169 | 0.73 | GRIN2B (0.66) | GRIN2BCYP2D6CYP2C9KDM4ECYP3A4 | |
| SCHEMBL4836692 | 0.73 | POLB (0.49) | MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289953-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6784182-B2 | AND FACTOR XA INHIBITORS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20020151724-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151724-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | GRIN2B 4499/4885CYP2D6 2052/4885CYP2C9 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.